Maintenance nifedipine therapy for preterm symptomatic placenta previa: A randomized, multicenter, double-blind, placebo-controlled trial

Eric Verspyck, Claire de Vienne, Charles Muszynski, Michael Bubenheim, Isabella Chanavaz-Lacheray, Michel Dreyfus, Philippe Deruelle, Jacques Benichou, Eric Verspyck, Claire de Vienne, Charles Muszynski, Michael Bubenheim, Isabella Chanavaz-Lacheray, Michel Dreyfus, Philippe Deruelle, Jacques Benichou

Abstract

Objective: To assess the impact of maintenance nifedipine therapy on pregnancy duration in women with preterm placenta previa bleeding.

Methods: PPADAL was a randomized, double-blind, placebo-controlled trial conducted between 05/2008 and 05/2012 in five French hospitals. The trial included 109 women, aged ≥ 18 years, with at least one episode of placenta previa bleeding, intact membranes and no other pregnancy complication, at gestational age 24 to 34 weeks and after 48 hours of complete acute tocolysis. Women were randomly allocated to receive either 20 mg of slow-release nifedipine three times daily (n = 54) or placebo (n = 55) until 36 + 6 weeks of gestation. The primary outcome for the trial was length of pregnancy measured in days after enrolment. Main secondary outcomes were rates of recurrent bleeding, cesarean delivery due to hemorrhage, blood transfusion, maternal side effects, gestational age at delivery and adverse perinatal outcomes (perinatal death, chronic lung disease, neonatal sepsis, intraventricular hemorrhage > grade 2, perventricular leukomalacia > grade 1, or necrotizing enterocolitis). Analysis was by intention to treat.

Results: Mean (SD) prolongation of pregnancy was not different between the nifedipine (n = 54) and the placebo (n = 55) group; 42.5 days ± 23.8 versus 44.2 days ± 24.5, p = 0.70. Cesarean due to hemorrhage performed before 37 weeks occurred more frequently in the nifedipine group in comparison with the placebo group (RR, 1.66; 95% confidence interval, 1.05-2.72). Adverse perinatal outcomes were comparable between groups; 3.8% for nifedipine versus 5.5% for placebo (relative risk, 0.52; 95% confidence interval 0.10-2.61). No maternal mortality or perinatal death occurred.

Conclusion: Maintenance oral nifedipine neither prolongs duration of pregnancy nor improves maternal or perinatal outcomes.

Trial registration: ClinicalTrials.gov NCT00620724.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Flow chart of study participants.
Fig 1. Flow chart of study participants.
Fig 2. Prolongation of pregnancy after randomization.
Fig 2. Prolongation of pregnancy after randomization.

References

    1. Iyasu S, Saftlas AK, Rowley DL, Koonin LM, awson HW, Atrash HK. The epidemiology of placenta previa in the United States, 1979 through 1987. Am J Obstet Gynecol. 1993;168(5):1424–9.
    1. Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: Twenty-year analysis. Am J Obstet Gynecol. 2005;192(5):1458–61. 10.1016/j.ajog.2004.12.074
    1. Knight M, Kurinczuk JJ, Spark P, Brocklehurst P; United Kingdom Obstetric Surveillance System Steering Committee. Cesarean delivery and peripartum hysterectomy. Obstet Gynecol. 2008;111(1):97–105. 10.1097/01.AOG.0000296658.83240.6d
    1. Ananth CV, Smulian JC, Vintzileos AM. The effect of placenta praevia on neonatal mortality: a population-based study in the United States, 1989 through 1997. Am J Obstet Gynecol. 2003;188(5):1299–1304.
    1. Silver R, Depp R, Sabbagha RE, Dooley SL, Socol ML, Tamura RK. Placenta previa: aggressive expectant management. Am J Obstet Gynecol. 1984;150(1):15–22.
    1. Royal College of Obstetricians and Gynecologists. Placenta praevia, placenta praevia accreta and vasa praevia: diagnosis and management. Green-top Guideline No. 27, third edn London: Royal College of Obstetricians and Gynecologists, 2011.
    1. Kayem G, Keita H. Management of placenta previa and accrete. French Guidelines. J Gynecol Obstet Biol Reprod. 2014, 43(10):1142–60.
    1. Magann EF, Johnson CA, Gookin KS, Roberts WE, Martin RW, Morrison JC. Placenta previa. Does uterine activity cause bleeding. Aus N Z J Obstet Gynecol 1993;33:22–4.
    1. Bose DA, Assel BG, Hill JB, Chauhan SP. Maintenance tocolytics for preterm symptomatic placenta previa: a review. Am J Perinatol. 2011;28(1):45–50. 10.1055/s-0030-1262510
    1. Besinger RE, Moniak CW, Paskiewicz LS, Fisher SG, Tomich PG The effect of tocolytic use in the management of symptomatic placenta previa. Am J Obstet Gynecol. 1995;172(6):1770–5.
    1. Sharma A, Suri V, Gupta I. Tocolytic therapy in conservative management of symptomatic placenta previa. Int J Gynaecol Obstet. 2004;84(2):109–13. 10.1016/S0020-7292(03)00198-X
    1. King JF, Flenady VJ, Paptsonis DNM, Dekker GA, Carbonne B. Calcium channel blockers for inhibiting preterm labor. Cochrane Database of Systematic Reviews. 2007;(4): CD002255.
    1. Guidelines AFSSAPS. Transfusion of homologous red blood cells: products, indications, alternative. . Published 2002.
    1. Wing DA, Paul RH, Millar LK. Management of the symptomatic placenta previa: a randomized, controlled trial of inpatient versus outpatient expectant management. Am J Obstet Gynecol. 1996;175(4):806–11.
    1. Oyelese Y, Smulian JC. Placenta previa, placenta accrete, and vasa previa. Obstet Gynecol. 2006;107(4):927–41. 10.1097/01.AOG.0000207559.15715.98
    1. Kayem G, Davy C, Goffinet F, Thomas C, Clement D, Cabrol D. Conservative versus extirpative management in cases of placenta accreta. Obstet Gynecol. 2004;104(3):531–6. 10.1097/01.AOG.0000136086.78099.0f
    1. Roos C, Spaanderman MEA, Schuit E, Bloemenkamp KWM, Bolte AC, Cornette J, et al., for the APOSTEL-II Study Group. Effect of Maintenance Tocolysis With Nifedipine in Threatened Preterm Labor on Perinatal Outcomes A Randomized Controlled Trial. JAMA. 2013;309(1):41–7. 10.1001/jama.2012.153817
    1. Sayin NC, Varol FG, Balkanli-Kaplan P, Sayin M. Oral nifedipine maintenance therapy after acute intravenous tocolysis in preterm labor. J Perinat Med. 2004;32(3):220–4. 10.1515/JPM.2004.041
    1. Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ. 2012;345:e6226 10.1136/bmj.e6226
    1. Oppenheimer LW, Farine D. A new classification of placenta previa. Am J Obstet Gynecol. 2009,201:227–9. 10.1016/j.ajog.2009.06.010
    1. Bhide A, Prefumo F, Moore J, Hollis B, Thilaganathan. Placental edge to internal os distance in the late third trimester and mode of delivery in placenta praevia. Br J Obstet Gynaecol. 2003;110(9):860–4.
    1. Love CDB, Wallace EM. Pregnancies complicated by placenta praevia: what is appropriate management Br J Obstet Gynaecol. 1996;103:864–7.
    1. Predanic M, Perni SC, Baergen RN, Claudel JP, Chasen ST, Chervenak FA. A Sonographic Assessment of Different Patterns of Placenta Previa “Migration” in the Third Trimester of Pregnancy. J Ultrasound Med. 2005; 24(6):773–80.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe